Biohedge Weekly
Biohedge Weekly summarizes SEC Schedule 13D/13G filings from biotech-focused hedge funds. We track 17 institutional investors with known biotech expertise.
RxDataLab RxDataLab links regulatory filings to clinical programs and markets, giving you the full picture of who's filing, what trials they're running, and how everything connects. Built for BD, investors, and strategy teams who need traceable data, not commentary.
Weekly Filing Volume
This week 3 institutional investors disclosed positions in 3 biotech companies via SEC Schedule 13D/13G filings. 1 new position.
Filings This Week
| Company | Fund | Ownership | Type |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | Deerfield Management | 4.3% | 13G/A [SEC] |
| Bright Minds Biosciences Pty Ltd (DRUG) | Cormorant Asset Management, LP | 10.9% | 13G/A [SEC] |
| HELIX ACQUISITION CORP II (HLXC) | RA Capital Management | 7.0% | New 13G [SEC] |
New Positions
Funds disclosing >5% ownership in a company for the first time.
| Company | Fund | Ownership | Type |
|---|---|---|---|
| HELIX ACQUISITION CORP II (HLXC) | RA Capital Management | 7.0% | SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses >5% ownership in a company for the first time.
We track 17 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.